



Investigating the Next-Generation of Cancer Therapies

Guest Editors:

Dr. Gregory F. Alberts

Dr. Richard Morgan

Dr. Terry Fisher

Dr. Ildiko Csiki

Deadline for manuscript
submissions:

closed (5 December 2018)

Message from the Guest Editors

Immunotherapy is a term that embodies new hope in the fight against cancer and other diseases, by exploiting the body's own immune system to fight disease, and was recognized by *Science Magazine* as the 2013 “Scientific Breakthrough of the Year”. After years of claiming that this year or that decade represented the “Golden Age of Biotechnology”, and though there have indeed been many notable discoveries and improvements on existing therapies and strategies, we are now on the cusp of implementing new and innovative cancer therapies that in many ways represent the first real return on the investments made in biotechnology over the past decades. From PD-1/PD-L1 antagonists or knockouts to the very latest in CAR-T therapies, there is justifiable optimism for the future of the treatment of cancer; there are myriad ways in which these new ideas can be exploited, some of which will be explored in the course of this issue.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)